CD8a (mouse)
- Known as:
- CD8a (mouse)
- Catalog number:
- 1F-579-C500
- Product Quantity:
- 0.5 mg
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD8a (mouse)
Related genes to: CD8a (mouse)
- Gene:
- CD8A NIH gene
- Name:
- CD8a molecule
- Previous symbol:
- CD8
- Synonyms:
- -
- Chromosome:
- 2p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: CD8a (mouse)
Related articles to: CD8a (mouse)
- Blood deficiency syndrome (BDS) is a systemic disorder characterized by hematopoietic dysfunction and immune dysregulation. Given the limitations of current therapies, such as single efficacy and adverse effects, there is an urgent need for multitarget therapeutic agents with systemic regulatory effects. In this study, a mouse model of BDS was established through chronic benzene inhalation. Using an integrated transcriptomics and proteomics approach, we systematically investigated the therapeutic mechanism of Danggui Buxue Decoction (DBD). The results demonstrated that DBD significantly restored body weight, thymic and splenic indices, and bone marrow microstructure in model mice but also improved peripheral blood parameters such as the red blood cell count and mean corpuscular volume. Furthermore, DBD coordinately modulated serum hematopoietic factor and inflammatory cytokine levels. Mechanistically, DBD exerts its therapeutic effects through dual pathways. On the one hand, it promotes hematopoietic repair by upregulating transferrin receptor (TFRC) to support iron-dependent erythropoiesis, modulating KITLG/FLT3LG to maintain stem cell pool stability, and reprogramming integrin expression (e.g., upregulating ITGA4 and downregulating ITGA1) to facilitate stem cell homing and suppress fibrosis. On the other hand, it reshapes the immune microenvironment by enhancing MHC class II antigen presentation (e.g., H2Aa, H2-Ab1, H2-DMb1, and H2-Eb1) and immune cell activation (e.g., CD22, CD37, CD20, and CD8a), thereby reestablishing immune homeostasis. This study provides a systematic molecular basis for the multitarget and holistic regulatory properties of DBD, supporting its clinical application and suggesting potential therapeutic targets for BDS-related disorders. - Source: PubMed
Publication date: 2026/05/22
Liu HongdaRen JunlingHu YuYang YuSun HuiFang HengYan GuangliHan YingWang Xijun - Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and remains a leading cause of cancer-related deaths worldwide. Despite advances in targeted therapies and immune checkpoint inhibitors, survival outcomes remain poor, underscoring the need for novel immune-related biomarkers to improve diagnosis, prognosis, and therapeutic strategies. - Source: PubMed
Publication date: 2026/05/22
Alghamdi AbdullahAlissa Mohammed - Patients undergoing lung cancer surgery experience significant systemic inflammatory responses and anesthetic interventions during the perioperative period, which can affect immune status and the tumor microenvironment. Different anesthetic techniques variably regulate inflammation, cytokine signaling, and tissue protection. It remains unclear, however, whether perioperative inflammatory signals leave identifiable molecular patterns at the tissue level. Furthermore, analyses integrating multi-layered data are currently lacking. We performed an integrated transcriptomic and single-cell analysis to identify shared molecular patterns linking perioperative inflammation, anesthetic modulation, and the lung cancer tumor microenvironment, and to localize these pathways to specific cellular communication axes. - Source: PubMed
Publication date: 2026/03/26
Lu WeixiangAi QingWang ZeZhang TaoDeng ShiyuHe JianxingShao Wenlong - Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis, characterized by a desmoplastic tumor microenvironment (TME) that limits immune cell infiltration and diminishes response to immunotherapy. Arylacetamide deacetylase (AADAC) is a lipid-processing enzyme, but its role in tumor progression, stromal organization, and immune modulation remains unclear. - Source: PubMed
Publication date: 2026/05/08
Wu ChaoYang Jun - This study aimed to identify and characterize irlncRNAs associated with prognosis and immune modulation in breast cancer. We integrated single-cell RNA sequencing, hdWGCNA, and bulk RNA-seq differential expression analysis results to identify candidate irlncRNAs. The top candidate, SIMALR, was further investigated using immune, survival, mutation analysis, and GSEA. RT-qPCR preliminary validation was performed on patient tissues. SIMALR was linked to favorable survival and enriched in immune pathways, including T-cell receptor signaling, Natural Killer (NK) cell cytotoxicity, and antigen processing. Pearson analysis showed co-expression of SIMALR-related genes (CD8A, CD4, TNF, LCP2, ITGB2) in key immune populations. High SIMALR As per standard instruction, "Statement of Significance" section should not be captured. Hence, the "Clinical significance" section was deleted. Please check and confirm if presented correctly; otherwise, please amend. expression in tumor cells is associated with enhanced secretion of Th1-attracting chemokines (CXCL9/10/11, CCL5), recruitment of CD8 + T cells, activated dendritic cells, and both M1/M2 macrophages. RT-qPCR confirmed higher SIMALR expression in tumors. Due to limited availability of clinical specimens, the RT-qPCR analysis was performed on paired tissue samples from six patients, and therefore the results should be considered a preliminary validation. SIMALR may contribute to anti-tumor immunity, highlighting its potential as a promising biomarker and therapeutic target in breast cancer. - Source: PubMed
Publication date: 2026/05/09
Balangi FatemehSamadi PouriaMaghool FatemehDaneshvar HamidTabatabaeian MaryamAmjadi ElhamSedghy Farnaz